Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Auinger

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Wiener Klinische Wochenschrift|December 25, 2012
[Diabetic nephropathy--update 2012]Martin Auinger, Roland Edlinger, Friedrich Prischl, et al.
Diabetes Care|April 29, 2006
Increased plasma amylin in type 1 diabetic patients after kidney and pancreas transplantation: A sign of impaired beta-cell function?Marietta Stadler, Christian Anderwald, Tina Karer, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2014
Mortality and incidence of renal replacement therapy in people with type 1 diabetes mellitus--a three decade long prospective observational study in the Lainz T1DM cohortMarietta Stadler, Slobodan Peric, Hermine Strohner-Kaestenbauer, et al.
Thrombosis Research|August 28, 2017
Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI)Oliver Königsbrügge, Matthias Lorenz, Martin Auinger, et al.
Wiener Klinische Wochenschrift|April 8, 2016
[Diabetic kidney disease - Update 2016]Harald Sourij, Roland Edlinger, Friedrich Prischl, et al.
Journal of the American Society of Nephrology : JASN|May 23, 2000
Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter studyGere Sunder-Plassmann, Manuela Födinger, Heidi Buchmayer, et al.
Journal of Thrombosis and Haemostasis : JTH|August 21, 2021
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort studyOliver Königsbrügge, Hannah Meisel, Aljoscha Beyer, et al.
Atherosclerosis|March 4, 2020
Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysisOliver Königsbrügge, Sabine Schmaldienst, Martin Auinger, et al.
Plos One|January 5, 2017
Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)Oliver Königsbrügge, Florian Posch, Marlies Antlanger, et al.
Wiener Klinische Wochenschrift|April 14, 2019
[Diabetic kidney disease (Update 2019) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology]Harald Sourij, Roland Edlinger, Friedrich C Prischl, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Wiener Klinische Wochenschrift|December 25, 2012
[Diabetic nephropathy--update 2012]Martin Auinger, Roland Edlinger, Friedrich Prischl, et al.
Diabetes Care|April 29, 2006
Increased plasma amylin in type 1 diabetic patients after kidney and pancreas transplantation: A sign of impaired beta-cell function?Marietta Stadler, Christian Anderwald, Tina Karer, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2014
Mortality and incidence of renal replacement therapy in people with type 1 diabetes mellitus--a three decade long prospective observational study in the Lainz T1DM cohortMarietta Stadler, Slobodan Peric, Hermine Strohner-Kaestenbauer, et al.
Thrombosis Research|August 28, 2017
Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI)Oliver Königsbrügge, Matthias Lorenz, Martin Auinger, et al.
Wiener Klinische Wochenschrift|April 8, 2016
[Diabetic kidney disease - Update 2016]Harald Sourij, Roland Edlinger, Friedrich Prischl, et al.
Journal of the American Society of Nephrology : JASN|May 23, 2000
Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter studyGere Sunder-Plassmann, Manuela Födinger, Heidi Buchmayer, et al.
Journal of Thrombosis and Haemostasis : JTH|August 21, 2021
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort studyOliver Königsbrügge, Hannah Meisel, Aljoscha Beyer, et al.
Atherosclerosis|March 4, 2020
Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysisOliver Königsbrügge, Sabine Schmaldienst, Martin Auinger, et al.
Plos One|January 5, 2017
Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)Oliver Königsbrügge, Florian Posch, Marlies Antlanger, et al.
Wiener Klinische Wochenschrift|April 14, 2019
[Diabetic kidney disease (Update 2019) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology]Harald Sourij, Roland Edlinger, Friedrich C Prischl, et al.
Pageof 3